Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versusstandard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)

Autor: Song, Alice T.W., Rocha, Vanderson, Mendrone-Júnior, Alfredo, Calado, Rodrigo T., De Santis, Gil C., Benites, Bruno D., Costa-Lima, Carolina, Vargas, Taiani, Marques, Leonardo S., Fernandes, Juliana C., Breda, Felipe C., Wendel, Silvano, Fachini, Roberta, Rizzo, Luiz V., Kutner, José Mauro, Avelino-Silva, Vivian I., Machado, Rafael R.G., Durigon, Edison L., Chevret, Sylvie, Kallas, Esper G.
Zdroj: The Lancet Regional Health - Americas; June 2022, Vol. 10 Issue: 1
Abstrakt: Administration of convalescent plasma may serve as an adjunct to supportive treatment to prevent COVID-19 progression and death. We aimed to evaluate the efficacy and safety of 2 volumes of intravenous convalescent plasma (CP) with high antibody titers for the treatment of severe cases of COVID-19.
Databáze: Supplemental Index